Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Drug Discov Today ; 28(11): 103769, 2023 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-37714405

RESUMEN

Transactive response DNA binding protein of 43 kDa (TDP-43) pathology is a common proteinopathy observed among a broad spectrum of patients with neurodegenerative disease, regardless of the mutation. This suggests that protein-protein interactions of TDP-43 with other proteins may in part be responsible for the pathology. To gain better insights, we investigated TDP-43-binding proteins in each domain and correlated these interactions with canonical pathways. These investigations revealed key cellular events that are involved and are important at each domain and suggested previously identified compounds to modulate key aspects of these canonical pathways. Our approach proposes that personalized medicine approaches, which focus on perturbed cellular mechanisms would be feasible in the near future.


Asunto(s)
Esclerosis Amiotrófica Lateral , Enfermedades Neurodegenerativas , Proteinopatías TDP-43 , Humanos , Proteinopatías TDP-43/genética , Proteinopatías TDP-43/metabolismo , Proteinopatías TDP-43/patología , Medicina de Precisión , Proteínas de Unión al ADN/metabolismo , Mutación
2.
Sci Rep ; 12(1): 5383, 2022 03 30.
Artículo en Inglés | MEDLINE | ID: mdl-35354901

RESUMEN

Even though amyotrophic lateral sclerosis (ALS) is a disease of the upper and lower motor neurons, to date none of the compounds in clinical trials have been tested for improving the health of diseased upper motor neurons (UMNs). There is an urgent need to develop preclinical assays that include UMN health as a readout. Since ALS is a complex disease, combinatorial treatment strategies will be required to address the mechanisms perturbed in patients. Here, we describe a novel in vitro platform that takes advantage of an UMN reporter line in which UMNs are genetically labeled with fluorescence and have misfolded SOD1 toxicity. We report that NU-9, an analog of the cyclohexane-1,3-dione family of compounds, improves the health of UMNs with misfolded SOD1 toxicity more effectively than riluzole or edaravone, -the only two FDA-approved ALS drugs to date-. Interestingly, when NU-9 is applied in combination with riluzole or edaravone, there is an additive effect on UMN health, as they extend longer axons and display enhanced branching and arborization, two important characteristics of healthy UMNs in vitro.


Asunto(s)
Esclerosis Amiotrófica Lateral , Riluzol , Esclerosis Amiotrófica Lateral/tratamiento farmacológico , Animales , Edaravona/farmacología , Humanos , Ratones , Neuronas Motoras , Riluzol/farmacología , Riluzol/uso terapéutico , Superóxido Dismutasa
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...